| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170483-100μg | 100μg | In stock | $109.90 | |
| Ab170483-1mg | 1mg | In stock | $507.90 | |
| Ab170483-5mg | 5mg | In stock | $1,377.90 | |
| Ab170483-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,187.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Monalizumab (anti-NKG2A) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to NKG2A, >95%, high purity, Human IgG4SP |
|---|---|
| Synonyms | CD159 antigen-like family member A | CD159a antigen | CD159a | C-lectin type II protein | killer cell lectin-like receptor subfamily C, member 1 | Klrc1 | MGC13374 | natural killer cell lectin | natural killer group protein 2 | NK cell receptor A | NKG2 | |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | NKG2A |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of killer cell lectin like receptor C1 (CD159a) |
| Product Description | Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC). |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG4SP |
| Light Chain Type | kappa |
| SDS-PAGE | 26.4 kDa (Light Chain) & 52.1 kDa (Heavy Chain), under reducing conditions; 175.2 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1228763-95-8 |
Monalizumab (anti-NKG2A) (Ab170483) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling NKG2A (red) with Monalizumab (anti-NKG2A) (Ab170483). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Monalizumab (anti-NKG2A) (Ab170483) - SEC
The purity of Monalizumab (anti-NKG2A) (Ab170483) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 562 |
|---|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0303666 | Certificate of Analysis | Mar 25, 2024 | Ab170483 |
| ZJ24F0303665 | Certificate of Analysis | Mar 25, 2024 | Ab170483 |
| ZJ24F0303664 | Certificate of Analysis | Mar 25, 2024 | Ab170483 |
| 1. Derré L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, Jotereau F, Gervois N. (2006) Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells.. J Immunol, 177 (5): (3100-7). [PMID:16920947] [10.1021/op500134e] |
| 2. Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C et al.. (2008) Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer.. Int J Oncol, 32 (3): (633-41). [PMID:18292941] [10.1021/op500134e] |
| 3. Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, Verneris MR, McGlave PB, Miller JS. (2010) Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade.. Biol Blood Marrow Transplant, 16 (5): (612-21). [PMID:20139023] [10.1021/op500134e] |
| 4. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G et al.. (2011) Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.. J Clin Invest, 121 (9): (3609-22). [PMID:21841316] [10.1021/op500134e] |
| 5. Silva TG, Crispim JC, Miranda FA, Hassumi MK, de Mello JM, Simões RT, Souto F, Soares EG, Donadi EA, Soares CP. (2011) Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness.. Histol Histopathol, 26 (12): (1487-97). [PMID:21972088] [10.1021/op500134e] |
| 6. Ruggeri L, Urbani E, André P, Mancusi A, Tosti A, Topini F, Bléry M, Animobono L, Romagné F, Wagtmann N et al.. (2016) Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.. Haematologica, 101 (5): (626-33). [PMID:26721894] [10.1021/op500134e] |
| 7. McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT. (2016) Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.. Oncoimmunology, 5 (10): (e1226720). [PMID:27853650] [10.1021/op500134e] |
| 8. Houchins JP, Yabe T, McSherry C, Bach FH. (1991) DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells.. J Exp Med, 173 (4): (1017-20). [PMID:2007850] [10.1021/op500134e] |
| 9. André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A et al.. (2018) Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.. Cell, 175 (7): (1731-1743.e13). [PMID:30503213] [10.1021/op500134e] |
| 10. Braud VM,Allan DS,O'Callaghan CA,Söderström K,D'Andrea A,Ogg GS,Lazetic S,Young NT,Bell JI,Phillips JH,Lanier LL,McMichael AJ. () HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.. Nature, [PMID:9486650] [http://pubmed.ncbi.nlm.nih.gov/9486650] |
| 11. Plougastel, B B, Jones, T T and Trowsdale, J J.. (1996) Genomic structure, chromosome location, and alternative splicing of the human NKG2A gene.. Immunogenetics, [PMID:8753859] |
| 12. Valiante, N M NM and 8 more authors.. (1997) Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors.. Immunity, [PMID:9430220] |
| 13. Le Dréan, E E and 9 more authors.. (1998) Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases.. European journal of immunology, [PMID:9485206] |
| 14. Plougastel, B B and Trowsdale, J J.. (1998) Sequence analysis of a 62-kb region overlapping the human KLRC cluster of genes.. Genomics, (15): [PMID:9598306] |
| 15. Kabat, Juraj J, Borrego, Francisco F, Brooks, Andrew A and Coligan, John E JE.. (2002) Role that each NKG2A immunoreceptor tyrosine-based inhibitory motif plays in mediating the human CD94/NKG2A inhibitory signal.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:12165520] |
| 16. Jabri, Bana B and 8 more authors.. (2002) TCR specificity dictates CD94/NKG2A expression by human CTL.. Immunity, [PMID:12387742] |
| 17. Nattermann, Jacob J and 9 more authors.. (2005) HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells.. Antiviral therapy, [PMID:15751767] |
| 18. Scherer, Steven E SE and 216 more authors.. (2006) The finished DNA sequence of human chromosome 12.. Nature, (16): [PMID:16541075] |
| 19. Bhagat, Govind G and 7 more authors.. (2008) Small intestinal CD8+TCRgammadelta+NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease.. The Journal of clinical investigation, [PMID:18064301] |
| 20. Sullivan, Lucy C LC and 14 more authors.. (2007) The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition.. Immunity, [PMID:18083576] |
| 21. Petrie, Emma J EJ and 12 more authors.. (2008) CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence.. The Journal of experimental medicine, (17): [PMID:18332182] |
| 22. Kaiser, Brett K BK, Pizarro, Juan Carlos JC, Kerns, Julie J and Strong, Roland K RK.. (2008) Structural basis for NKG2A/CD94 recognition of HLA-E.. Proceedings of the National Academy of Sciences of the United States of America, (6): [PMID:18448674] |
| 23. Angelini, Daniela F DF and 10 more authors.. (2011) NKG2A inhibits NKG2C effector functions of γδ T cells: implications in health and disease.. Journal of leukocyte biology, [PMID:20952657] |
| 24. Heatley, Susan L SL and 14 more authors.. (2013) Polymorphism in human cytomegalovirus UL40 impacts on recognition of human leukocyte antigen-E (HLA-E) by natural killer cells.. The Journal of biological chemistry, (22): [PMID:23335510] |
| 25. Bortolotti, Daria; Gentili, Valentina; Rizzo, Sabrina; Rotola, Antonella and Rizzo, Roberta.. (2020) SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.. Cells, (26): [PMID:32859121] |
